Ipinzan (Metformin Hydrochloride, Vildagliptin)

Ipinzan, a combination of metformin and vildagliptin, is used in the management of type 2 diabetes mellitus.

• Type 2 diabetes mellitus (initial therapy): helps achieve target HbA1c when combined with diet and exercise.
• Type 2 diabetes mellitus (add‑on to metformin): provides additional glucose lowering when metformin alone is insufficient.
• Type 2 diabetes mellitus (dual therapy): offers combined action on hepatic glucose production and incretin pathway for better glycemic control.

• Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby lowering fasting glucose. Vildagliptin inhibits the enzyme dipeptidyl peptidase‑4, which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP). The increased incretin effect enhances glucose‑dependent insulin secretion and suppresses glucagon release, complementing metformin’s action to improve overall glycemic control.

Ipinzan may be associated with a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
• Upper respiratory tract infection: mild cold‑like symptoms.
• Headache: transient mild headache.
• Hypoglycemia (when combined with other glucose‑lowering agents): symptoms of low blood sugar.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic complication.
• Severe hypersensitivity: skin rash, angioedema, or anaphylactic reactions.
• Pancreatitis: acute inflammation of the pancreas.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before prescribing Ipinzan, several precautions should be considered to ensure safe use.

• Renal function assessment: evaluate creatinine clearance before initiation and periodically during therapy.
• Hepatic disease monitoring: avoid in patients with significant liver impairment due to risk of lactic acidosis.
• Concomitant medication review: caution when used with other antidiabetic agents that may cause hypoglycemia.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; consult healthcare provider.
• Cardiovascular status: monitor in patients with unstable heart disease as metformin may affect cardiac function.
• Store at ambient temperature: keep below 25 °C, protect from moisture, and retain in original packaging.

Ipinzan can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; discontinue metformin before imaging.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vildagliptin plasma levels, raising risk of hypoglycemia.
• Cimetidine: reduces renal clearance of metformin, increasing exposure.
• Alcohol excess: enhances risk of metformin‑related lactic acidosis.

Moderate Interactions (Monitor Closely)

• Sulfonylureas or insulin: additive glucose‑lowering effect may cause hypoglycemia; monitor blood glucose.
• Diuretics (thiazides): may affect renal function and metformin clearance.
• NSAIDs (high dose): may impair renal function, increasing metformin accumulation.